The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.
FDA Study on BPA: Nothing’s Changed Since February
You may recall a March 5, WasteWatcher blog, “New FDA Report on BPA: It is Still Safe,” which discussed a pre-peer review draft study released by the National Toxicology Program (NTP) on bisphenol A (BPA), a compound used to produce plastic products and epoxy resins used in food and beverage can linings. The study, two-years […]
The Fourth Circuit Was Right to Reject Price Controls for Generic Drugs
This prudent decision will send a strong message to other state legislatures across the country not to pursue similar legislation.
Obamacare is Bringing BIG Changes
The Patient Protection and Affordable Care Act, or Obamacare, is bringing many changes in the healthcare space and few are as subtly transformative as the rapid increase in cross-industry consolidation. A record breaking 115 mergers and acquisitions among hospitals and health systems occurred in 2017, an increase of 13 percent from 2016. These mega-deals can […]
Stealing Patents Won’t Bring Down Drug Costs
On February 15, 2018, 18 Democratic members of Congress sent a letter to Health and Human Services (HHS) Secretary Alex Azar, asking him to use his authority under 28 U.S.C. §1498 to issue a compulsory license on patents for drugs that treat hepatitis C. In other words, they are demanding that the government steal a […]
A Moment of Truth: Will Virginia Republicans Expand Medicaid?
On April 11, 2018, Virginia legislators will return to Richmond for a special session in which they will aim to finish work on the Commonwealth’s budget. At center stage, yet again, is the issue of Medicaid expansion, still unresolved eight years after Obamacare became law. Medicaid is a deeply flawed program that was meant to […]
Any Willing Pharmacy – Not as Good as it Sounds
On November 28, 2017, the Centers for Medicare and Medicaid Services (CMS) published a proposed rule that would revise Medicare Part D, the prescription drug program. The proposal dredges up the “any willing pharmacy” issue that would require any Part D plan sponsor, such as an insurer or a pharmacy benefit manager (PBM), to allow […]
The VA Scandal Refuses to End
Countless investigations over the past decade have exposed a systemic cancer of mismanagement, neglect, and failure at the VA.
The BBA, Medicare Part D, and a Cautionary Tale
When President Trump signed the Bipartisan Budget Act (BBA) for fiscal years 2018 and 2019 on February 9, 2018, Citizens Against Government Waste (CAGW) objected because of its prolific and irresponsible spending, calling the $300 billion (14 percent) increase over current levels “outrageous and unnecessary, as well as a complete abdication of fiscal discipline and […]
New FDA Report on BPA: It is Still Safe
On February 23, 2018, the Food and Drug Administration (FDA) released a statement by Deputy Commissioner for Foods and Veterinary Medicine Stephen Ostroff, M.D., regarding a draft report issued by the National Toxicology Program (NTP) on the compound bisphenol A, more commonly referred to as BPA. The report concluded that BPA, the compound used to […]